Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

Clare Robertson; Shona Fielding; Andrew Walker; Daniel Kopasker; Thenmalar Vadiveloo; Paul Manson; Gillian Price; Miriam Brazzelli; Graham Scotland

Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

Clare Robertson, Shona Fielding, Andrew Walker, Daniel Kopasker, Thenmalar Vadiveloo, Paul Manson, Gillian Price, Miriam Brazzelli, Graham Scotland

Research output: Book/Report › Commissioned Report

Abstract

Lorlatinib is recommended, within its marketing authorisation, as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults whose disease has progressed after:

- alectinib or ceritinib as the first ALK tyrosine kinase inhibitor or

- crizotinib and at least 1 other ALK tyrosine kinase inhibitor.

It is recommended only if the company provides lorlatinib according to the commercial arrangement.

Original language	English
Publisher	Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence
Commissioning body	National Institute for Health and Care Excellence
Publication status	Published - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@book{40c8e0eb57664faf99fc659bd070a66b,

title = "Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer",

abstract = "Lorlatinib is recommended, within its marketing authorisation, as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults whose disease has progressed after:- alectinib or ceritinib as the first ALK tyrosine kinase inhibitor or- crizotinib and at least 1 other ALK tyrosine kinase inhibitor.It is recommended only if the company provides lorlatinib according to the commercial arrangement.",

author = "Clare Robertson and Shona Fielding and Andrew Walker and Daniel Kopasker and Thenmalar Vadiveloo and Paul Manson and Gillian Price and Miriam Brazzelli and Graham Scotland",

year = "2019",

language = "English",

publisher = "Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence",

}

TY - BOOK

T1 - Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

AU - Robertson, Clare

AU - Fielding, Shona

AU - Walker, Andrew

AU - Kopasker, Daniel

AU - Vadiveloo, Thenmalar

AU - Manson, Paul

AU - Price, Gillian

AU - Brazzelli, Miriam

AU - Scotland, Graham

PY - 2019

Y1 - 2019

N2 - Lorlatinib is recommended, within its marketing authorisation, as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults whose disease has progressed after:- alectinib or ceritinib as the first ALK tyrosine kinase inhibitor or- crizotinib and at least 1 other ALK tyrosine kinase inhibitor.It is recommended only if the company provides lorlatinib according to the commercial arrangement.

AB - Lorlatinib is recommended, within its marketing authorisation, as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults whose disease has progressed after:- alectinib or ceritinib as the first ALK tyrosine kinase inhibitor or- crizotinib and at least 1 other ALK tyrosine kinase inhibitor.It is recommended only if the company provides lorlatinib according to the commercial arrangement.

UR - https://www.nice.org.uk/guidance/ta628

M3 - Commissioned Report

BT - Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

PB - Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence

ER -

Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this